Knight Reports Fourth Quarter and Year Ended December 31, 2014 Results
(firmenpresse) - MONTREAL, QUEBEC -- (Marketwired) -- 03/19/15 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"), a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2014.
Highlights
Financial Results Reported in Canadian Dollars
For the quarter ended December 31, 2014, the Company reported revenues of $109,608 and net income of $124,981,439. For the year ended December 31, 2014, the Company reported revenues of $365,323 and net income of $125,858,872. As at December 31, 2014, the Company had $416,8 million in cash and marketable securities and 90,818,595 common shares outstanding.
"I said from the beginning that Knight won't rest until it is at least as successful as Paladin, and after one year of operations, I can confidently say that we are off to a GUD start," said Jonathan Ross Goodman, President and CEO of Knight Therapeutics Inc. "In the year ahead, we look forward to expanding our team to focus on strategy execution and continuing to build our pipeline of innovative specialty products."
Conference Call Notice
Knight will host a conference call to discuss its fourth quarter and year end results today at 8:30 am ET. Investors and other interested parties may call 1-877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922 (local or international).
A taped replay of the conference call will be available from today at 11:30 a.m. ET until Sunday, April 19, 2015 at 11:59 p.m ET. To access the replay, please call 1-800-585-8367 or 416-621-4642 and use access code 32217419.
Knight expects to release its first quarter 2015 financial results on the morning of Wednesday, May 13, 2015.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight's shares began trading on TSX-V on March 3, 2014 and graduated to TSX on April 29, 2014 under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's website at or at .
Forward-Looking Statement
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the Company's Listing Application dated February 21, 2014 and its short form prospectus dated December 16, 2014. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
CONSOLIDATED BALANCE SHEETS
(In Canadian dollars)
As at December 31
CONSOLIDATED STATEMENTS OF INCOME
(In Canadian dollars)
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In Canadian dollars)
CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
(In Canadian dollars)
CONSOLIDATED STATEMENT OF CASH FLOWS
(In Canadian dollars)
The following amounts are classified within operating activities:
Contacts:
Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-GUD1 (4831)
514-481-4116 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.03.2015 - 10:00 Uhr
Sprache: Deutsch
News-ID 379629
Anzahl Zeichen: 0
contact information:
Town:
MONTREAL, QUEBEC
Kategorie:
Drugs
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Knight Reports Fourth Quarter and Year Ended December 31, 2014 Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Knight Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
